Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 558

1.

Psychometric performance of the PAncreatic CAncer disease impact (PACADI) score.

Heiberg T, Baekelandt B, Kvien TK, Buanes T.

Pancreatology. 2019 Sep 2. pii: S1424-3903(19)30720-3. doi: 10.1016/j.pan.2019.09.001. [Epub ahead of print]

2.

Trends in all-cause and cardiovascular mortality in patients with incident rheumatoid arthritis: a 20-year follow-up matched case-cohort study.

Provan SA, Lillegraven S, Sexton J, Angel K, Austad C, Haavardsholm EA, Kvien TK, Uhlig T.

Rheumatology (Oxford). 2019 Aug 29. pii: kez371. doi: 10.1093/rheumatology/kez371. [Epub ahead of print]

PMID:
31504942
3.

Associations between ultrasound-detected synovitis, pain and function in interphalangeal and thumb base osteoarthritis: Data from the Nor-Hand study.

Fjellstad CM, Mathiessen A, Slatkowsky-Christensen B, Kvien TK, Hammer HB, Haugen IK.

Arthritis Care Res (Hoboken). 2019 Aug 17. doi: 10.1002/acr.24047. [Epub ahead of print]

PMID:
31421023
4.

Biomarkers of cardiovascular risk across phenotypes of osteoarthritis.

Provan SA, Rollefstad S, Ikdahl E, Mathiessen A, Berg IJ, Eeg I, Wilkinson IB, McEniery CM, Kvien TK, Hammer HB, Østerås N, Haugen IK, Semb AG.

BMC Rheumatol. 2019 Aug 8;3:33. doi: 10.1186/s41927-019-0081-8. eCollection 2019.

5.

Four-year follow-up of inflammatory arthropathy patients treated with golimumab: Data from the observational multicentre NOR-DMARD study.

Michelsen B, Sexton J, Wierød A, Bakland G, Rødevand E, Krøll F, Kvien TK.

Semin Arthritis Rheum. 2019 Jul 12. pii: S0049-0172(19)30082-4. doi: 10.1016/j.semarthrit.2019.07.003. [Epub ahead of print]

PMID:
31358361
6.

Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis.

Lauper K, Mongin D, Iannone F, Kristianslund EK, Kvien TK, Nordström DC, Pavelka K, Pombo-Suarez M, Rotar Z, Santos MJ, Codreanu C, Lukina G, Gale SL, John M, Luder Y, Courvoisier DS, Gabay C.

Semin Arthritis Rheum. 2019 Jun 28. pii: S0049-0172(19)30203-3. doi: 10.1016/j.semarthrit.2019.06.020. [Epub ahead of print]

7.

Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials.

Curtis JR, Mariette X, Gaujoux-Viala C, Blauvelt A, Kvien TK, Sandborn WJ, Winthrop K, de Longueville M, Huybrechts I, Bykerk VP.

RMD Open. 2019 May 31;5(1):e000942. doi: 10.1136/rmdopen-2019-000942. eCollection 2019.

8.

Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution.

Lauper K, Mongin D, Alpizar-Rodriguez D, Codreanu C, Iannone F, Kristianslund EK, Kvien TK, Pavelka K, Pombo-Suarez M, Santos MJ, Gabay C, Finckh A, Courvoisier DS.

Rheumatology (Oxford). 2019 Jun 17. pii: kez221. doi: 10.1093/rheumatology/kez221. [Epub ahead of print]

PMID:
31209481
9.

Swollen, but not tender joints, are independently associated with ultrasound synovitis: results from a longitudinal observational study of patients with established rheumatoid arthritis.

Hammer HB, Michelsen B, Sexton J, Haugen IK, Provan SA, Haavardsholm EA, Uhlig T, Kvien TK.

Ann Rheum Dis. 2019 Sep;78(9):1179-1185. doi: 10.1136/annrheumdis-2019-215321. Epub 2019 Jun 6.

PMID:
31171525
10.

Validation of the Intermittent and Constant Osteoarthritis Pain Questionnaire in Patients with Hand Osteoarthritis: Results from the Nor-Hand Study.

Gløersen M, Steen Pettersen P, Kvien TK, Haugen IK.

J Rheumatol. 2019 Jun;46(6):645-651. doi: 10.3899/jrheum.180835. Epub 2019 Mar 15.

PMID:
30877221
11.

Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial.

Goll GL, Jørgensen KK, Sexton J, Olsen IC, Bolstad N, Haavardsholm EA, Lundin KEA, Tveit KS, Lorentzen M, Berset IP, Fevang BTS, Kalstad S, Ryggen K, Warren DJ, Klaasen RA, Asak Ø, Baigh S, Blomgren IM, Brenna Ø, Bruun TJ, Dvergsnes K, Frigstad SO, Hansen IM, Hatten ISH, Huppertz-Hauss G, Henriksen M, Hoie SS, Krogh J, Midtgard IP, Mielnik P, Moum B, Noraberg G, Poyan A, Prestegård U, Rashid HU, Strand EK, Skjetne K, Seeberg KA, Torp R, Ystrøm CM, Vold C, Zettel CC, Waksvik K, Gulbrandsen B, Hagfors J, Mørk C, Jahnsen J, Kvien TK.

J Intern Med. 2019 Jun;285(6):653-669. doi: 10.1111/joim.12880. Epub 2019 Apr 12.

PMID:
30762274
12.

Peripheral and Central Sensitization of Pain in Individuals With Hand Osteoarthritis and Associations With Self-Reported Pain Severity.

Steen Pettersen P, Neogi T, Magnusson K, Berner Hammer H, Uhlig T, Kvien TK, Haugen IK.

Arthritis Rheumatol. 2019 Jul;71(7):1070-1077. doi: 10.1002/art.40850. Epub 2019 May 14.

PMID:
30741501
13.

Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider.

Unger J, Putrik P, Buttgereit F, Aletaha D, Bianchi G, Bijlsma JWJ, Boonen A, Cikes N, Dias JM, Falzon L, Finckh A, Gossec L, Kvien TK, Matteson EL, Sivera F, Stamm TA, Szekanecz Z, Wiek D, Zink A, Dejaco C, Ramiro S.

RMD Open. 2018 Dec 5;4(2):e000756. doi: 10.1136/rmdopen-2018-000756. eCollection 2018.

14.

EULAR 'points to consider' for the conduction of workforce requirement studies in rheumatology.

Dejaco C, Putrik P, Unger J, Aletaha D, Bianchi G, Bijlsma JW, Boonen A, Cikes N, Finckh A, Gossec L, Kvien TK, Madruga Dias J, Matteson EL, Sivera F, Stamm TA, Szekanecz Z, Wiek D, Zink A, Ramiro S, Buttgereit F.

RMD Open. 2018 Dec 5;4(2):e000780. doi: 10.1136/rmdopen-2018-000780. eCollection 2018.

15.

Clinical trial and 'real-world' data support switching from a bio-originator to its biosimilar.

Kay J, Dörner T, Emery P, Kvien TK, Breedveld FC.

Ann Rheum Dis. 2019 Jan 18. pii: annrheumdis-2018-214994. doi: 10.1136/annrheumdis-2018-214994. [Epub ahead of print] No abstract available.

16.

Fibromyalgia in patients with rheumatoid arthritis. A 10-year follow-up study, results from the Oslo Rheumatoid Arthritis Register.

Provan SA, Austad C, Halsaa V, Hammer HB, Kvien TK, Uhlig T.

Clin Exp Rheumatol. 2019 Jan-Feb;37 Suppl 116(1):58-62. Epub 2019 Jan 8.

17.

Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial.

Nordberg LB, Lillegraven S, Aga AB, Sexton J, Olsen IC, Lie E, Berner Hammer H, Uhlig T, van der Heijde D, Kvien TK, Haavardsholm EA.

RMD Open. 2018 Nov 16;4(2):e000752. doi: 10.1136/rmdopen-2018-000752. eCollection 2018.

18.

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.

Coates LC, Gladman DD, Nash P, FitzGerald O, Kavanaugh A, Kvien TK, Gossec L, Strand V, Rasouliyan L, Pricop L, Ding K, Jugl SM, Gaillez C; FUTURE 2 study group.

Arthritis Res Ther. 2018 Dec 7;20(1):272. doi: 10.1186/s13075-018-1773-y.

19.

Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry.

Olsen IC, Lie E, Vasilescu R, Wallenstein G, Strengholt S, Kvien TK.

Rheumatology (Oxford). 2019 Mar 1;58(3):481-491. doi: 10.1093/rheumatology/key338.

20.

Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries.

Lauper K, Mongin D, Iannone F, Klami Kristianslund E, Kvien TK, Nordström D, Pavelka K, Pombo-Suarez M, Rotar Z, Santos MJ, Codreanu C, Lukina G, Courvoisier DS, Gabay C.

RMD Open. 2018 Nov 5;4(2):e000809. doi: 10.1136/rmdopen-2018-000809. eCollection 2018.

21.

Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study.

Norvang V, Sexton J, Kristianslund EK, Olsen IC, Uhlig T, Bakland G, Krøll F, Rødevand E, Wierød A, Kvien TK, Smolen JS, Aletaha D, Haavardsholm EA.

RMD Open. 2018 Oct 26;4(2):e000773. doi: 10.1136/rmdopen-2018-000773. eCollection 2018.

22.

DAPSA and ultrasound show different perspectives of psoriatic arthritis disease activity: results from a 12-month longitudinal observational study in patients starting treatment with biological disease-modifying antirheumatic drugs.

Pukšić S, Bolton-King P, Sexton J, Michelsen B, Kvien TK, Berner Hammer H.

RMD Open. 2018 Nov 5;4(2):e000765. doi: 10.1136/rmdopen-2018-000765. eCollection 2018.

23.

Comparative analyses of responsiveness between the Rheumatoid Arthritis Impact of Disease score, other patient-reported outcomes and disease activity measures: secondary analyses from the ARCTIC study.

Holten K, Sexton J, Kvien TK, Aga AB, Haavardsholm EA.

RMD Open. 2018 Oct 26;4(2):e000754. doi: 10.1136/rmdopen-2018-000754. eCollection 2018.

24.

Tender joint count may not reflect inflammatory activity in established rheumatoid arthritis patients - results from a longitudinal study.

Hammer HB, Michelsen B, Provan SA, Sexton J, Lampa J, Uhlig T, Kvien TK.

Arthritis Care Res (Hoboken). 2018 Nov 26. doi: 10.1002/acr.23815. [Epub ahead of print]

PMID:
30474932
25.

Feasibility of cardiovascular disease risk assessments in rheumatology outpatient clinics: experiences from the nationwide NOCAR project.

Ikdahl E, Rollefstad S, Wibetoe G, Salberg A, Krøll F, Bergsmark K, Kvien TK, Olsen IC, Soldal DM, Bakland G, Lexberg Å, Gjesdal CG, Gulseth C, Haugeberg G, Semb AG.

RMD Open. 2018 Oct 1;4(2):e000737. doi: 10.1136/rmdopen-2018-000737. eCollection 2018.

26.

Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent.

Kristensen LE, Alten R, Puig L, Philipp S, Kvien TK, Mangues MA, van den Hoogen F, Pavelka K, Vulto AG.

BioDrugs. 2018 Oct;32(5):397-404. doi: 10.1007/s40259-018-0306-1.

27.

Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaboration.

Chatzidionysiou K, Lukina G, Gabay C, Hetland ML, Hauge EM, Pavelka K, Nordström D, Canhão H, Tomsic M, Rotar Z, Lie E, Kvien TK, van Vollenhoven RF, Saevarsdottir S.

Scand J Rheumatol. 2019 Jan;48(1):17-23. doi: 10.1080/03009742.2018.1466363. Epub 2018 Sep 27.

PMID:
30260261
28.

Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints?

Michelsen B, Sexton J, Smolen JS, Aletaha D, Krogh NS, van der Heijde D, Kvien TK, Hetland ML.

Ann Rheum Dis. 2018 Dec;77(12):1736-1741. doi: 10.1136/annrheumdis-2018-213463. Epub 2018 Sep 20.

PMID:
30237203
29.

Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE 2 study.

Deodhar A, Conaghan PG, Kvien TK, Strand V, Sherif B, Porter B, Jugl SM, Gandhi KK; MEASURE 2 study group.

Clin Exp Rheumatol. 2019 Mar-Apr;37(2):260-269. Epub 2018 Jul 19.

PMID:
30148436
30.

Biological treatment in ankylosing spondylitis in the Nordic countries during 2010-2016: a collaboration between five biological registries.

Glintborg B, Lindström U, Aaltonen K, Kristianslund EK, Gudbjornsson B, Chatzidionysiou K, Askling J, Nordström D, Hetland ML, Di Giuseppe D, Dreyer L, Kristensen LE, Jørgensen TS, Eklund K, Grondal G, Ernestam S, Joensuu J, Törmänen M, Skydsgaard H, Hagfors J, Kvien TK, Lie E, Fagerli K, Geirsson AJ, Jonsson H, Provan SA, Krogh NS, Jacobsson L.

Scand J Rheumatol. 2018 Nov;47(6):465-474. doi: 10.1080/03009742.2018.1444199. Epub 2018 Aug 2.

PMID:
30070923
31.

Predictors of sustained remission in patients with early rheumatoid arthritis treated according to an aggressive treat-to-target protocol.

Paulshus Sundlisæter N, Olsen IC, Aga AB, Hammer HB, Uhlig T, van der Heijde D, Kvien TK, Lillegraven S, Haavardsholm EA; ARCTIC study group.

Rheumatology (Oxford). 2018 Nov 1;57(11):2022-2031. doi: 10.1093/rheumatology/key202.

PMID:
30053199
32.

Guideline recommended treatment to targets of cardiovascular risk is inadequate in patients with inflammatory joint diseases.

Ikdahl E, Wibetoe G, Rollefstad S, Salberg A, Bergsmark K, Kvien TK, Olsen IC, Soldal DM, Bakland G, Lexberg Å, Fevang BTS, Gulseth HC, Haugeberg G, Semb AG.

Int J Cardiol. 2019 Jan 1;274:311-318. doi: 10.1016/j.ijcard.2018.06.111. Epub 2018 Jul 2.

PMID:
30007486
33.

Associations Between Cardiorespiratory Fitness and Arterial Stiffness in Ankylosing Spondylitis: A Cross-sectional Study.

Berg IJ, Semb AG, Sveaas SH, Fongen C, van der Heijde D, Kvien TK, Dagfinrud H, Provan SA.

J Rheumatol. 2018 Nov;45(11):1522-1525. doi: 10.3899/jrheum.170726. Epub 2018 Jul 1.

PMID:
29961684
34.

Clinical and ultrasound remission after 6 months of treat-to-target therapy in early rheumatoid arthritis: associations to future good radiographic and physical outcomes.

Paulshus Sundlisæter N, Aga AB, Olsen IC, Hammer HB, Uhlig T, van der Heijde D, Kvien TK, Lillegraven S, Haavardsholm EA; ARCTIC study group.

Ann Rheum Dis. 2018 Oct;77(10):1421-1425. doi: 10.1136/annrheumdis-2017-212830. Epub 2018 Jun 22.

PMID:
29934373
35.

New-generation JAK inhibitors: how selective can they be?

Goll GL, Kvien TK.

Lancet. 2018 Jun 23;391(10139):2477-2478. doi: 10.1016/S0140-6736(18)31325-4. Epub 2018 Jun 13. No abstract available.

PMID:
29908671
36.

Health-related quality of life in patients with psoriatic and rheumatoid arthritis: data from the prospective multicentre NOR-DMARD study compared with Norwegian general population controls.

Michelsen B, Uhlig T, Sexton J, van der Heijde D, Hammer HB, Kristianslund EK, Wierød A, Bakland G, Rødevand E, Krøll F, Loge JH, Haugeberg G, Kvien TK.

Ann Rheum Dis. 2018 Sep;77(9):1290-1294. doi: 10.1136/annrheumdis-2018-213286. Epub 2018 Jun 6.

PMID:
29875096
37.

Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration.

Lauper K, Nordström DC, Pavelka K, Hernández MV, Kvien TK, Kristianslund EK, Santos MJ, Rotar Ž, Iannone F, Codreanu C, Lukina G, Gale SL, Sarsour K, Luder Y, Courvoisier DS, Gabay C.

Ann Rheum Dis. 2018 Sep;77(9):1276-1282. doi: 10.1136/annrheumdis-2017-212845. Epub 2018 May 5.

PMID:
29730637
38.

Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example.

Chatzidionysiou K, Hetland ML, Frisell T, Di Giuseppe D, Hellgren K, Glintborg B, Nordström D, Aaltonen K, Törmänen MR, Klami Kristianslund E, Kvien TK, Provan SA, Björn Guðbjörnsson B, Dreyer L, Kristensen LE, Jørgensen TS, Jacobsson L, Askling J.

RMD Open. 2018 Apr 12;4(1):e000655. doi: 10.1136/rmdopen-2018-000655. eCollection 2018. Review. Erratum in: RMD Open. 2018 May 14;4(1):.

39.

The confidence of rheumatologists about switching to biosimilars for their patients.

Goll GL, Haavardsholm EA, Kvien TK.

Joint Bone Spine. 2018 Oct;85(5):507-509. doi: 10.1016/j.jbspin.2018.03.009. Epub 2018 Apr 6. No abstract available.

PMID:
29631065
40.

The Impact of Ultrasound on the Use and Efficacy of Intraarticular Glucocorticoid Injections in Early Rheumatoid Arthritis: Secondary Analyses From a Randomized Trial Examining the Benefit of Ultrasound in a Clinical Tight Control Regimen.

Nordberg LB, Lillegraven S, Aga AB, Sexton J, Lie E, Hammer HB, Olsen IC, Uhlig T, van der Heijde D, Kvien TK, Haavardsholm EA.

Arthritis Rheumatol. 2018 Aug;70(8):1192-1199. doi: 10.1002/art.40494. Epub 2018 Jun 29.

41.

Improving the peer review skills of young rheumatologists and researchers in rheumatology: the EMEUNET Peer Review Mentoring Program.

Rodríguez-Carrio J, Putrik P, Sepriano A, Moltó A, Nikiphorou E, Gossec L, Kvien TK, Ramiro S.

RMD Open. 2018 Feb 16;4(1):e000619. doi: 10.1136/rmdopen-2017-000619. eCollection 2018. Review.

42.

Phrasing of the patient global assessment in the rheumatoid arthritis ACR/EULAR remission criteria: an analysis of 967 patients from two databases of early and established rheumatoid arthritis patients.

Gossec L, Kirwan JR, de Wit M, Balanescu A, Gaujoux-Viala C, Guillemin F, Rat AC, Saraux A, Fautrel B, Kvien TK, Dougados M; RAID investigators.

Clin Rheumatol. 2018 Jun;37(6):1503-1510. doi: 10.1007/s10067-018-3998-1. Epub 2018 Feb 21.

PMID:
29468340
43.

Response to: 'Depression and anxiety associate with less remission after 1 year in rheumatoid arthritis' by Boer et al.

Michelsen B, Kvien TK.

Ann Rheum Dis. 2019 Jan;78(1):e2. doi: 10.1136/annrheumdis-2017-212910. Epub 2018 Jan 22. No abstract available.

PMID:
29358284
44.

Response to: 'Calprotectin is not independent from baseline erosion in predicting radiological progression in early rheumatoid arthritis' by Chevreau et al.

Jonsson MK, Sundlisæter NP, Nordal HH, Hammer HB, Aga AB, van der Heijde D, Kvien TK, Fevang BS, Lillegraven S, Haavardsholm EA.

Ann Rheum Dis. 2018 Dec;77(12):e85. doi: 10.1136/annrheumdis-2017-212869. Epub 2018 Jan 10. No abstract available.

PMID:
29321158
45.

Diagnostic spectrum and 2-year outcome in a cohort of patients with very early arthritis.

Norli ES, Brinkmann GH, Kvien TK, Bjørneboe O, Haugen AJ, Nygaard H, Thunem C, Lie E, Mjaavatten MD.

RMD Open. 2017 Dec 22;3(2):e000573. doi: 10.1136/rmdopen-2017-000573. eCollection 2017.

46.

Deriving common comorbidity indices from the MedDRA classification and exploring their performance on key outcomes in patients with rheumatoid arthritis.

Putrik P, Ramiro S, Lie E, Michaud K, Kvamme MK, Keszei AP, Kvien TK, Uhlig T, Boonen A.

Rheumatology (Oxford). 2018 Mar 1;57(3):548-554. doi: 10.1093/rheumatology/kex440.

PMID:
29272517
47.

Discrepancies in risk age and relative risk estimations of cardiovascular disease in patients with inflammatory joint diseases.

Wibetoe G, Ikdahl E, Rollefstad S, Olsen IC, Bergsmark K, Kvien TK, Salberg A, Soldal DM, Bakland G, Lexberg Å, Fevang BT, Gulseth HC, Haugeberg G, Semb AG.

Int J Cardiol. 2018 Feb 1;252:201-206. doi: 10.1016/j.ijcard.2017.10.038.

PMID:
29249429
48.

Efficacy of infliximab biosimilars in patients with Crohn's disease - Authors' reply.

Jørgensen KK, Lundin KE, Olsen IC, Kvien TK, Jahnsen J.

Lancet. 2017 Dec 2;390(10111):2436. doi: 10.1016/S0140-6736(17)32463-7. Epub 2017 Dec 1. No abstract available.

PMID:
29208304
49.

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis.

Coates LC, FitzGerald O, Merola JF, Smolen J, van Mens LJJ, Bertheussen H, Boehncke WH, Callis Duffin K, Campbell W, de Wit M, Gladman D, Gottlieb A, James J, Kavanaugh A, Kristensen LE, Kvien TK, Luger T, McHugh N, Mease P, Nash P, Ogdie A, Rosen CF, Strand V, Tillett W, Veale DJ, Helliwell PS.

Arthritis Rheumatol. 2018 Mar;70(3):345-355. doi: 10.1002/art.40391. Epub 2018 Feb 6.

50.

Remission in psoriatic arthritis-where are we now?

Coates LC, Conaghan PG, D'Agostino MA, De Wit M, FitzGerald O, Kvien TK, Lories R, Mease P, Nash P, Schett G, Soriano ER, Emery P.

Rheumatology (Oxford). 2018 Aug 1;57(8):1321-1331. doi: 10.1093/rheumatology/kex344.

Supplemental Content

Loading ...
Support Center